Deep China Price Cuts Reveal Complex Considerations
This article was originally published in PharmAsia News
Offering deep price discounts in exchange for inclusion in reimbursement lists is never easy, given companies' need to balance expected benefits in volume gains with their international pricing systems and commercial pressures. But in China the underlying considerations are even more complex, as shown by the latest round of national price reductions for selected drugs.
Register for our free email digests: